Advertisement
Editorial Comment|Articles in Press

Measuring Clinically Important Changes in Patients With Heart Failure

  • CHRISTOPHER V. CHIEN
    Correspondence
    Reprint requests: Christopher Chien, MD, Department of Medicine, Division of Cardiology, University of North Carolina at Chapel Hill, 160 Dental Circle, CB 7075, Burnett-Womack Building, Chapel Hill, NC 27599-7075.
    Affiliations
    Department of Medicine, Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC

    UNC Rex Healthcare, Raleigh, NC
    Search for articles by this author
  • LINDSEY A. ROSMAN
    Affiliations
    Department of Medicine, Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC
    Search for articles by this author
      Knowing how patients interpret changes in functional capacity is essential for translating standardized measures such as the 6-minute-walk-test (6MWT) into a meaningful patient-reported outcome (PRO). The 6MWT is a well-validated, commonly collected measure of exercise capacity in heart failure (HF) clinical trials. However, it is often reduced to a surrogate endpoint, whereby the clinical significance is defined solely by its relationship to adverse outcomes such as death or hospitalization.
      • Psotka MA
      • Abraham WT
      • Fiuzat M
      • Filippatos G
      • Lindenfeld J
      • Ahmad T
      • et al.
      Functional and symptomatic clinical trial endpoints: the HFC-ARC Scientific Expert Panel.
      Alternatively, establishing a minimal clinically important difference (MCID) in the 6MWT that is anchored to a quality-of-life tool allows us to understand how much change in functional status is meaningful to patients—a much more patient-centered and often clinically relevant question.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Psotka MA
        • Abraham WT
        • Fiuzat M
        • Filippatos G
        • Lindenfeld J
        • Ahmad T
        • et al.
        Functional and symptomatic clinical trial endpoints: the HFC-ARC Scientific Expert Panel.
        JACC Heart Fail. 2022; 10: 889-901
        • Khan MS
        • Anker SD
        • Friede T
        • Jankowska EA
        • Metra M
        • Piña IL
        • et al.
        Minimal clinically important differences in 6-minute walk test in patients with HFrEF and iron deficiency.
        J Card Fail. 2022; (S1071-9164(22)01173-3Epub ahead of print. PMID: 36332897)https://doi.org/10.1016/j.cardfail.2022.10.423
        • Anker SD
        • Comin Colet J
        • Filippatos G
        • Willenheimer R
        • Dickstein K
        • Drexler H
        • et al.
        Ferric carboxymaltose in patients with heart failure and iron deficiency.
        N Engl J Med. 2009; 361: 2436-2448
        • Ponikowski P
        • van Veldhuisen DJ
        • Comin-Colet J
        • Ertl G
        • Komajda M
        • Mareev V
        • et al.
        Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency.
        Eur Heart J. 2015; 36: 657-668
        • Shoemaker MJ
        • Curtis AB
        • Vangsnes E
        • Dickinson MG.
        Triangulating clinically meaningful change in the six-minute walk test in individuals with chronic heart failure: a systematic review.
        Cardiopulm Phys Ther J. 2012; 23: 5-15
        • Uszko-Lencer NHMK
        • Mesquita R
        • Janssen E
        • Werter C
        • Brunner-La Rocca HP
        • et al.
        Reliability, construct validity and determinants of 6-minute walk test performance in patients with chronic heart failure.
        Int J Cardiol. 2017; 240: 285-290
        • Wright A
        • Hannon J
        • Hegedus EJ
        • Kavchak AE.
        Clinimetrics corner: a closer look at the minimal clinically important difference (MCID).
        J Man Manip Ther. 2012; 20: 160-166
        • Spertus J
        • Peterson E
        • Conard MW
        • Heidenreich PA
        • Krumholz HM
        • Jones P
        • et al.
        Monitoring clinical changes in patients with heart failure: a comparison of methods.
        Am Heart J. 2005; 150: 707-715
        • Mentz RJ
        • Ambrosy AP
        • Ezekowitz JA
        • Lewis GD
        • Butler J
        • Wong YW
        • et al.
        HEART-FID Trial Investigators.Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design.
        Circ Heart Fail. 2021; 14 (Epub 2021 May 18. PMID: 34003690; PMCID: PMC8136455)e008100https://doi.org/10.1161/CIRCHEARTFAILURE.120.008100

      Linked Article

      • Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency
        Journal of Cardiac Failure
        • Preview
          Impaired functional capacity is common in patients with heart failure (HF).1 With increasing focus on patient preference for better overall health status, in addition to a reduction in the use of traditional disease-specific endpoints, such as morbidity and mortality,2,3 therapeutic targets in patients with HF have expanded to encompass improvements in functional capacity and health status (health-related quality of life).4 The 6-minute walk test (6MWT) is an indicator of exercise capacity and prognosis in various cardiopulmonary conditions.
        • Full-Text
        • PDF
        Open Access